Abstract
We have coined the term “Malignant Obesity Hypoventilation Syndrome” (MOHS) to describe a severe multisystem disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity related hypoventilation together with systemic hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension and hepatic dysfunction. Patients with MOHS are frequently admitted to the ICU with hypercapnic respiratory failure and have a high mortality. This syndrome is largely unrecognized as physicians do not make the association between the patients’ multiple medical problems and obesity. Due to the delayed diagnosis and progressive morbidities of this condition all patients with a BMI > 40 kg/m2 should be screened for MOHS. The management of patients with MOHS includes short term measures to improve the patients’ medical condition and long term measures to achieve enduring weight loss. Bariatric surgery reverses or improves the multiple metabolic and organ dysfunctions associated with MOHS and should be strongly considered in these patients.
Keywords: Diabetes, diastolic heart failure, metabolic syndrome, myocardial hypotrophy, non-acholic steato-hepatitis, obesity, obesity hypoventilation syndrome, pulmonary hypertension.
Current Respiratory Medicine Reviews
Title:The Malignant Obesity Hypoventilation Syndrome (MOHS)
Volume: 10 Issue: 4
Author(s): Paul E. Marik and Joseph Varon
Affiliation:
Keywords: Diabetes, diastolic heart failure, metabolic syndrome, myocardial hypotrophy, non-acholic steato-hepatitis, obesity, obesity hypoventilation syndrome, pulmonary hypertension.
Abstract: We have coined the term “Malignant Obesity Hypoventilation Syndrome” (MOHS) to describe a severe multisystem disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity related hypoventilation together with systemic hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension and hepatic dysfunction. Patients with MOHS are frequently admitted to the ICU with hypercapnic respiratory failure and have a high mortality. This syndrome is largely unrecognized as physicians do not make the association between the patients’ multiple medical problems and obesity. Due to the delayed diagnosis and progressive morbidities of this condition all patients with a BMI > 40 kg/m2 should be screened for MOHS. The management of patients with MOHS includes short term measures to improve the patients’ medical condition and long term measures to achieve enduring weight loss. Bariatric surgery reverses or improves the multiple metabolic and organ dysfunctions associated with MOHS and should be strongly considered in these patients.
Export Options
About this article
Cite this article as:
E. Marik Paul and Varon Joseph, The Malignant Obesity Hypoventilation Syndrome (MOHS), Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666150427223059
DOI https://dx.doi.org/10.2174/1573398X11666150427223059 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Ionophores as Potent Anti-malarials: A Miracle in the Making
Current Topics in Medicinal Chemistry Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Current Alzheimer Research Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design New Heterocyclic Compounds: Synthesis, Antioxidant Activity and Computational Insights of Nano-Antioxidant as Ascorbate Peroxidase Inhibitor by Various Cyclodextrins as Drug Delivery Systems
Current Drug Delivery Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Chemistry and Biology of Gluten Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Systems Biology and Biomechanical Model of Heart Failure
Current Cardiology Reviews